{"id":"midodrine-pyridostigmine","safety":{"commonSideEffects":[{"rate":null,"effect":"Supine hypertension"},{"rate":null,"effect":"Piloerection"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midodrine is an alpha-1 adrenergic agonist that directly increases peripheral vasoconstriction and blood pressure. Pyridostigmine is an acetylcholinesterase inhibitor that enhances parasympathetic tone and can improve blood pressure regulation through central and peripheral mechanisms. The combination is used to address orthostatic hypotension through complementary pathways.","oneSentence":"Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:17.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Orthostatic hypotension"}]},"trialDetails":[{"nctId":"NCT02893553","phase":"PHASE2","title":"The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2016-12","conditions":"Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity","enrollment":21},{"nctId":"NCT02308124","phase":"PHASE4","title":"Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-11","conditions":"Orthostatic; Hypotension, Neurogenic","enrollment":87},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":"Autonomic Failure, Orthostatic Hypotension","enrollment":389}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combination"],"phase":"marketed","status":"active","brandName":"Midodrine + pyridostigmine","genericName":"Midodrine + pyridostigmine","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability. Used for Orthostatic hypotension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}